{{Rsnum
|rsid=2837960
|Gene=LINC00323
|Chromosome=21
|position=41139991
|Orientation=plus
|GMAF=0.2071
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 1.8 | 25.7 | 72.6
| HCB | 5.1 | 29.2 | 65.7
| JPT | 0.9 | 23.0 | 76.1
| YRI | 9.5 | 44.9 | 45.6
| ASW | 8.8 | 52.6 | 38.6
| CHB | 5.1 | 29.2 | 65.7
| CHD | 4.6 | 30.3 | 65.1
| GIH | 4.0 | 30.7 | 65.3
| LWK | 8.2 | 59.1 | 32.7
| MEX | 0.0 | 12.1 | 87.9
| MKK | 13.5 | 41.0 | 45.5
| TSI | 3.9 | 29.4 | 66.7
| HapMapRevision=28
}}
[[rs2837960]] has been reported in a large study to be associated with [[rheumatoid arthritis]].

The risk allele (oriented to the dbSNP entry) is (G); the odds ratio associated with heterozygotes is 0.95 (CI 0.83-1.08), and for homozygotes, 2.30 (CI 1.64-3.23). {{PMID|17554300|OA=1
}}

{{GWAS Summary
|SNP=rs2837960
|PubMedID=17554300
|Condition=Rheumatoid arthritis
|Gene=NR
|Risk Allele=G
|pValue=2.00E-006
|OR=1.05
|95CI=0.93-1.20
|OA=1
}}

{{PharmGKB
|RSID=rs2837960
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17554300; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (Initial Sample Size: 1,860 cases, 2,938 controls; Replication Sample Size: NR; Risk Allele: rs2837960-G). This variant is associated with Rheumatoid arthritis.
|Drugs=
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356650
}}

{{PMID Auto
|PMID=21595938
|Title=Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer's disease
|OA=1
}}

{{PMID|18794857|OA=1
}} Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13.

{{PMID|20017963|OA=1
}} Representation of genetic association via attributable familial relative risks in order to identify polymorphisms functionally relevant to rheumatoid arthritis.

{{PMID|20426808|OA=1
}} AntEpiSeeker: detecting epistatic interactions for case-control studies using a two-stage ant colony optimization algorithm.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2837960
|overall_frequency_n=35
|overall_frequency_d=126
|overall_frequency=0.277778
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}